Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fukushima Medical University
With
Human Genome Center, Institute of Medical Science, University of Tokyo
The prognosis of pancreatic cancer is extremely poor even with extensive surgery, chemotherapy or radiation. It has been required development of new treatment modalities. Immunotherapy is one of the encouraging modalities for cancer patients. The investigators have to assess its toxicities and immune responsiveness.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer
